Kelesitse Phiri1, Paige L Williams, Kate B Dugan, Michael A Fischer, William O Cooper, George R Seage, Sonia Hernandez-Diaz. 1. From the *Department of Epidemiology, †Department of Biostatics, Harvard School of Public Health, Boston, MA; ‡Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; §Department of Preventive Medicine, and ¶Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN.
Abstract
BACKGROUND: Several studies have assessed the association between antiretroviral (ARV) therapy use during pregnancy and small for gestational age (SGA), but the evidence remains incompletely elucidated. METHODS: We linked data from Tennessee Medicaid files and vital records to evaluate pregnancies among human immunodeficiency virus (HIV)-infected women who delivered between 1994 and 2009. Maternal HIV status was defined based on diagnosis codes, ARV prescriptions and laboratory codes for CD4 count or HIV RNA assays. ARV use was identified from pharmacy claims. Risk of SGA (defined as birth weight below the 10th percentile for gestational age) and preterm birth was evaluated using logistic regression models. RESULTS: Four hundred and seventy-seven HIV-infected pregnant women contributing 604 singleton pregnancies were identified; 156 (26%) delivered SGA infants. ARV use during pregnancy was not associated with SGA [adjusted odds ratio: 0.93; 95% confidence interval (CI): 0.56-1.56] or preterm birth (adjusted odds ratio: 0.74; 95% CI: 0.42-1.32). Exposure to a protease inhibitor during the first trimester was associated with a lower risk of SGA (odds ratio: 0.54; 95% CI: 0.29-1.01) compared with non-exposure to a protease inhibitor throughout pregnancy. CONCLUSIONS: We observed no evidence of an association between ARV exposure during pregnancy and SGA delivery in this Medicaid cohort of HIV-infected women.
BACKGROUND: Several studies have assessed the association between antiretroviral (ARV) therapy use during pregnancy and small for gestational age (SGA), but the evidence remains incompletely elucidated. METHODS: We linked data from Tennessee Medicaid files and vital records to evaluate pregnancies among human immunodeficiency virus (HIV)-infectedwomen who delivered between 1994 and 2009. Maternal HIV status was defined based on diagnosis codes, ARV prescriptions and laboratory codes for CD4 count or HIV RNA assays. ARV use was identified from pharmacy claims. Risk of SGA (defined as birth weight below the 10th percentile for gestational age) and preterm birth was evaluated using logistic regression models. RESULTS: Four hundred and seventy-seven HIV-infected pregnant women contributing 604 singleton pregnancies were identified; 156 (26%) delivered SGA infants. ARV use during pregnancy was not associated with SGA [adjusted odds ratio: 0.93; 95% confidence interval (CI): 0.56-1.56] or preterm birth (adjusted odds ratio: 0.74; 95% CI: 0.42-1.32). Exposure to a protease inhibitor during the first trimester was associated with a lower risk of SGA (odds ratio: 0.54; 95% CI: 0.29-1.01) compared with non-exposure to a protease inhibitor throughout pregnancy. CONCLUSIONS: We observed no evidence of an association between ARV exposure during pregnancy and SGA delivery in this Medicaid cohort of HIV-infectedwomen.
Authors: Kelesitse Phiri; Sonia Hernandez-Diaz; Kate B Dugan; Paige L Williams; Judith A Dudley; Astride Jules; S Todd Callahan; George R Seage; William O Cooper Journal: Pediatr Infect Dis J Date: 2014-07 Impact factor: 2.129
Authors: Anne B Morris; Ana Rua Dobles; Susan Cu-Uvin; Carmen Zorrilla; Jean Anderson; Joseph I Harwell; Jean Keller; Jane Garb Journal: J Acquir Immune Defic Syndr Date: 2005-09-01 Impact factor: 3.731
Authors: Kunjal Patel; David E Shapiro; Susan B Brogly; Elizabeth G Livingston; Alice M Stek; Arlene D Bardeguez; Ruth E Tuomala Journal: J Infect Dis Date: 2010-04-01 Impact factor: 5.226
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: E S Machado; C B Hofer; T T Costa; S A Nogueira; R H Oliveira; T F Abreu; L A Evangelista; I F A Farias; R T C Mercadante; M F L Garcia; R C Neves; V M Costa; J S Lambert Journal: Sex Transm Infect Date: 2008-11-05 Impact factor: 3.519
Authors: Arlene D Bardeguez; Jane C Lindsey; Maureen Shannon; Ruth E Tuomala; Susan E Cohn; Elizabeth Smith; Alice Stek; Shelly Buschur; Amanda Cotter; Linda Bettica; Jennifer S Read Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731
Authors: Jean B Nachega; Olalekan A Uthman; Jean Anderson; Karl Peltzer; Sarah Wampold; Mark F Cotton; Edward J Mills; Yuh-Shan Ho; Jeffrey S A Stringer; James A McIntyre; Lynne M Mofenson Journal: AIDS Date: 2012-10-23 Impact factor: 4.177
Authors: Ruth E Tuomala; David E Shapiro; Lynne M Mofenson; Yvonne Bryson; Mary Culnane; Michael D Hughes; M J O'Sullivan; Gwendolyn Scott; Alice M Stek; Diane Wara; Marc Bulterys Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Ingrid J M Snijdewind; Colette Smit; Mieke H Godfried; Rachel Bakker; Jeannine F J B Nellen; Vincent W V Jaddoe; Elisabeth van Leeuwen; Peter Reiss; Eric A P Steegers; Marchina E van der Ende Journal: PLoS One Date: 2018-01-19 Impact factor: 3.240
Authors: Anne Esther Njom Nlend; Annie Nga Motazé; Suzie Moyo Tetang; Cécile Zeudja; Marcus Ngantcha; Mathurin Tejiokem Journal: PLoS One Date: 2016-03-21 Impact factor: 3.240